KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inovio Pharmaceuticals (INO) Total Liabilities (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed Total Liabilities for 16 consecutive years, with $50.2 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities rose 12.35% to $50.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $50.2 million through Dec 2025, up 12.35% year-over-year, with the annual reading at $50.2 million for FY2025, 12.35% up from the prior year.
  • Total Liabilities hit $50.2 million in Q4 2025 for Inovio Pharmaceuticals, down from $77.1 million in the prior quarter.
  • In the past five years, Total Liabilities ranged from a high of $161.7 million in Q2 2022 to a low of $33.5 million in Q3 2024.
  • Historically, Total Liabilities has averaged $71.6 million across 5 years, with a median of $65.5 million in 2023.
  • Biggest five-year swings in Total Liabilities: crashed 67.57% in 2021 and later surged 130.03% in 2025.
  • Year by year, Total Liabilities stood at $96.3 million in 2021, then surged by 31.06% to $126.2 million in 2022, then crashed by 57.52% to $53.6 million in 2023, then dropped by 16.62% to $44.7 million in 2024, then increased by 12.35% to $50.2 million in 2025.
  • Business Quant data shows Total Liabilities for INO at $50.2 million in Q4 2025, $77.1 million in Q3 2025, and $39.7 million in Q2 2025.